IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 98.3

Change

-0.03 (-0.03)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.31 (-0.20%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

-0.12 (-0.16%)

USD 3.01B
FXH First Trust Health Care AlphaD..

-0.50 (-0.45%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.47 (-0.52%)

USD 0.23B
IDNA iShares Genomics Immunology an..

+0.10 (+0.41%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.19 (-0.49%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-0.39 (-0.40%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.19%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.08 (-0.13%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.16 (+0.55%)

USD 0.01B

ETFs Containing IXJ

XHC:CA iShares Global Healthcare.. 99.91 % 0.65 %

-0.26 (-0.60%)

CAD 0.66B
IXJ:AU iShares Global Healthcare.. 99.88 % 0.00 %

-0.86 (-0.60%)

USD 1.46B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.35% 76% C+ 66% D+
Dividend Return 0.78% 75% C 16% F
Total Return 14.13% 71% C- 61% D-
Trailing 12 Months  
Capital Gain 18.59% 43% F 54% F
Dividend Return 1.48% 89% A- 22% F
Total Return 20.07% 43% F 49% F
Trailing 5 Years  
Capital Gain 61.12% 71% C- 75% C
Dividend Return 6.29% 78% C+ 19% F
Total Return 67.41% 71% C- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 7.46% 67% D+ 63% D
Dividend Return 8.42% 67% D+ 58% F
Total Return 0.96% 74% C 22% F
Risk Return Profile  
Volatility (Standard Deviation) 10.69% 95% A 76% C+
Risk Adjusted Return 78.77% 81% B- 89% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike